Navigation Links
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
Date:9/25/2008

EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) today announced that previously found excess symptomatic intracranial hemorrhage in an earlier European trial of ancrod (now Viprinex(TM)) for the treatment of acute ischemic stroke may be minimized with avoidance of prolonged low levels of fibrinogen and use of common blood pressure entry criteria.

The data, presented today at the 6th World Stroke Conference in Vienna, Austria, are from a retrospective analysis led by NTI scientists of two previous Phase 3 clinical trials, known as STAT and ESTAT, which involved more than 1700 patients and were conducted before NTI acquired the rights to ancrod. The STAT trial in the United States showed ancrod-treated patients had a better outcome than placebo-treated patients, while the European ESTAT trial showed an ancrod treatment outcome similar to placebo, but a higher rate of symptomatic intracranial hemorrhages. When the drug safety information from the trials were compared, it was noted that patients treated with ancrod in ESTAT who had symptomatic intracranial hemorrhages were more likely to have had prolonged low fibrinogen blood levels, to have received higher doses of ancrod and to have had higher blood pressures at trial entry.

"The conclusions of this analysis provided NTI with the information needed to revise the dosing regimen to avoid prolonged low fibrinogen levels and launch new Phase 3 clinical trials using common blood pressure patient-entry criteria," says Gregory del Zoppo, M.D. of the University of Washington, chairman of the current ancrod clinical trials' steering committee, and a coauthor of the retrospective analysis.

"Earlier Viprinex trials
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... CAMBRIDGE, Mass. , Oct. 22, 2014 ... Cambridge, MA is revolutionizing spinal cord ... technique has been shown to outperform in tissue regrowth ... with the scaffold.  Made from an FDA approved polymer, ... dioxide; making it harmless to the human body. NVIV ...
(Date:10/22/2014)... and AUSTIN, Texas , Oct. ... LLC today announced they have entered into a ... immunotherapies designed to target cancers. PhosImmune ... displayed on the surfaces of tumor cells in ... (PTTs), derived from proteins that play a role ...
(Date:10/22/2014)... Oct. 22, 2014  Recently published clinical studies of ... already substantial database of evidence. This data has led ... Stretta therapy for sufferers of refractory GERD. ... supporting Stretta therapy as a safe and effective ... Stretta therapy available to nearly 50 million Americans. The ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2
... Reportlinker.com announces that a new market research report ... Global Vertebral Compression Fracture Devices Industry ... analyzes the Global market for Vertebral Compression Fracture ... are provided for the period 2006 through 2015. ...
... that a new market research report is available in ... http://www.reportlinker.com/p0155051/Antidiabetics-market-forecast.html ... billion in 2019 for the seven major markets. Januvia ... expiry of Actos, with franchise sales reaching nearly $6 ...
Cached Medicine Technology:Reportlinker Adds Global Vertebral Compression Fracture Devices Industry 2Reportlinker Adds Global Vertebral Compression Fracture Devices Industry 3Reportlinker Adds Global Vertebral Compression Fracture Devices Industry 4Reportlinker Adds Global Vertebral Compression Fracture Devices Industry 5Reportlinker Adds Antidiabetics Market Forecast 2
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
(Date:10/20/2014)... Florida (PRWEB) October 20, 2014 With ... former Gov. Charlie Crist made a brief fundraising stop ... Orlando on Thursday. , Fresh from a debate last ... to take the stage for the first seven minutes ... the former governor described the incident in one word: ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 T.E.N., ... relationship-marketing firm, announced today that William H. Murray, ... the 2014 ISE® Luminary Leadership Award winner. Presented ... achievements of an outstanding leader and industry practitioner ... contributions in advancing the information security industry. , ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... study in the Aug. 1 issue of the journal Sleep ... infants are easier to arouse than females during quiet sleep, and ... gender differences in arousability. The results suggest that the increased ... reflect a pre-existing vulnerability involving arousal responses. Results show that ...
... Teenage years have long been linked with a heightened ... and tout happiness as just a nip/tuck away. A RutgersCamden ... programs are more likely to join the millions who go ... - still in development, these drastic decisions could have implications ...
... LANSING, Mich. - With the help of a $2.5 ... State University is creating a cross-discipline, mentored program designed ... women,s health., MSU,s new Building Interdisciplinary Research Careers in ... of Medicine in the College of Human Medicine, will ...
... strain, ST131, was a major cause of serious antimicrobial-resistant ... researchers found. This strain has been reported in multiple countries ... study, researchers analyzed resistant E. coli isolates collected ... 54 ST131 isolates, which accounted for 67 percent to 69 ...
... CD74 is a protein that is expressed in and ... lymphocytes and antigen presenting cells. This protein is known ... immune response. Additionally, Professor Shachar,s lab has previously shown ... of the immune system, and that its stimulation by ...
... refers to a group of disorders characterized by ... bile ducts. Multiple causes have been identified including ... medications. The usual course of this condition is ... treatment of the underlying condition and/ or removal ...
Cached Medicine News:Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 2Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 3Health News:Reality TV, cosmetic surgey linked, says Rutgers-Camden researcher 2Health News:MSU targets women's health research with $2.5 million grant 2Health News:Vanishing bile duct syndrome secondary to anti-retroviral therapy in HIV 2
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: